|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Hara K, Beppu T, Kimura M, Fujita Y,
Takata T, Nishio K and Ono N: Influence of novel supramolecular
substance, [2] rotaxane, on the caspase signaling pathway in
melanoma and colon cancer cells in vitro. J Pharmacol Sci.
122:153–157. 2013. View Article : Google Scholar
|
|
4
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng L, Ren W, Xie L, Li M, Liu J, Hu J,
Liu BR and Qian XP: Anti-EGFR MoAb treatment in colorectal cancer:
Limitations, controversies, and contradictories. Cancer Chemother
Pharmacol. 74:1–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hellwig CT and Rehm M: TRAIL signaling and
synergy mechanisms used in TRAIL-based combination therapies. Mol
Cancer Ther. 11:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han B, Yao W, Oh YT, Tong JS, Li S, Deng
J, Yue P, Khuri FR and Sun SY: The novel proteasome inhibitor
carfilzomib activates and enhances extrinsic apoptosis involving
stabilization of death receptor 5. Oncotarget. 6:17532–17542. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ashkenazi A, Holland P and Eckhardt SG:
Ligand-based targeting of apoptosis in cancer: The potential of
recombinant human apoptosis ligand 2/Tumor necrosis factor-related
apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol.
26:3621–3630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koehler BC, Jäger D and Schulze-Bergkamen
H: Targeting cell death signaling in colorectal cancer: Current
strategies and future perspectives. World J Gastroenterol.
20:1923–1934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kelley SK, Harris LA, Xie D, Deforge L,
Totpal K, Bussiere J and Fox JA: Preclinical studies to predict the
disposition of Apo2L/tumor necrosis factor-related
apoptosis-inducing ligand in humans: Characterization of in vivo
efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther.
299:31–38. 2001.PubMed/NCBI
|
|
11
|
Kim SL, Liu YC, Park YR, Seo SY, Kim SH,
Kim IH, Lee SO, Lee ST, Kim DG and Kim SW: Parthenolide enhances
sensitivity of colorectal cancer cells to TRAIL by inducing death
receptor 5 and promotes TRAIL-induced apoptosis. Int J Oncol.
46:1121–1130. 2015. View Article : Google Scholar
|
|
12
|
Skerra A: Lipocalins as a scaffold.
Biochim Biophys Acta. 1482:337–350. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang J, Goetz D, Li JY, Wang W, Mori K,
Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, et al: An
iron delivery pathway mediated by a lipocalin. Mol Cell.
10:1045–1056. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Devireddy LR, Gazin C, Zhu X and Green MR:
A cell-surface receptor for lipocalin 24p3 selectively mediates
apoptosis and iron uptake. Cell. 123:1293–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nielsen BS, Borregaard N, Bundgaard JR,
Timshel S, Sehested M and Kjeldsen L: Induction of NGAL synthesis
in epithelial cells of human colorectal neoplasia and inflammatory
bowel diseases. Gut. 38:414–420. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sanjeevani S, Pruthi S, Kalra S, Goel A
and Kalra OP: Role of neutrophil gelatinase-associated lipocalin
for early detection of acute kidney injury. Int J Crit Illn Inj
Sci. 4:223–228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan C, Yuanjie T, Zhengqun X, Jiayan C and
Kongdan L: Neutrophil gelatinase-associated lipocalin attenuates
ischemia/ reperfusion injury in an in vitro model via autophagy
activation. Med Sci Monit. 24:479–485. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y
and Kim JS: Ectopic expression of neutrophil gelatinase-associated
lipocalin suppresses the invasion and liver metastasis of colon
cancer cells. Int J Cancer. 118:2490–2497. 2006. View Article : Google Scholar
|
|
19
|
Kim SL, Lee ST, Min IS, Park YR, Lee JH,
Kim DG and Kim SW: Lipocalin 2 negatively regulates cell
proliferation and epithelial to mesenchymal transition through
changing metabolic gene expression in colorectal cancer. Cancer
Sci. 108:2176–2186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Irmler M, Thome M, Hahne M, Schneider P,
Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C,
et al: Inhibition of death receptor signals by cellular FLIP.
Nature. 388:190–195. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scaffidi C, Schmitz I, Zha J, Korsmeyer
SJ, Krammer PH and Peter ME: Differential modulation of apoptosis
sensitivity in CD95 type I and type II cells. J Biol Chem.
274:22532–22538. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nicholson DW, Ali A, Thornberry NA,
Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle
M, Lazebnik YA, et al: Identification and inhibition of the
ICE/CED-3 protease necessary for mammalian apoptosis. Nature.
376:37–43. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tewari M, Quan LT, O’Rourke K, Desnoyers
S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM:
Yama/CPP32 beta, a mammalian homolog of CED-3, is a
CrmA-inhibitable protease that cleaves the death substrate
poly(ADP-ribose) polymerase. Cell. 81:801–809. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim EY, Ryu JH and Kim AK: CAPE promotes
TRAIL-induced apoptosis through the upregulation of TRAIL receptors
via activation of p38 and suppression of JNK in SK-Hep1
hepatocellular carcinoma cells. Int J Oncol. 43:1291–1300. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lepage C, Léger DY, Bertrand J, Martin F,
Beneytout JL and Liagre B: Diosgenin induces death receptor-5
through activation of p38 pathway and promotes TRAIL-induced
apoptosis in colon cancer cells. Cancer Lett. 301:193–202. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ohtsuka T, Buchsbaum D, Oliver P, Makhija
S, Kimberly R and Zhou T: Synergistic induction of tumor cell
apoptosis by death receptor antibody and chemotherapy agent through
JNK/p38 and mitochondrial death pathway. Oncogene. 22:2034–2044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pennati M, Sbarra S, De Cesare M,
Lopergolo A, Locatelli SL, Campi E, Daidone MG, Carlo-Stella C,
Gianni AM and Zaffaroni N: YM155 sensitizes triple-negative breast
cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated
DR5 upregulation. Int J Cancer. 136:299–309. 2015. View Article : Google Scholar
|
|
29
|
Wang XZ and Ron D: Stress-induced
phosphorylation and activation of the transcription factor CHOP
(GADD153) by p38 MAP Kinase. Science. 272:1347–1349. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamaguchi H and Wang HG: CHOP is involved
in endoplasmic reticulum stress-induced apoptosis by enhancing DR5
expression in human carcinoma cells. J Biol Chem. 279:45495–45502.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ozören N and El-Deiry WS: Cell surface
Death Receptor signaling in normal and cancer cells. Semin Cancer
Biol. 13:135–147. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
den Hollander MW, Gietema JA, de Jong S,
Walenkamp AM, Reyners AK, Oldenhuis CN and de Vries EG: Translating
TRAIL-receptor targeting agents to the clinic. Cancer Lett.
332:194–201. 2013. View Article : Google Scholar
|
|
33
|
Yoshida T, Zhang Y, Rivera Rosado LA and
Zhang B: Repeated treatment with subtoxic doses of TRAIL induces
resistance to apoptosis through its death receptors in MDA-MB-231
breast cancer cells. Mol Cancer Res. 7:1835–1844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin Z, McDonald ER III, Dicker DT and
El-Deiry WS: Deficient tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) death receptor transport to the
cell surface in human colon cancer cells selected for resistance to
TRAIL-induced apoptosis. J Biol Chem. 279:35829–35839. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wainberg ZA, Messersmith WA, Peddi PF,
Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC and Kozloff MF: A
phase 1B study of dulanermin in combination with modified FOLFOX6
plus bevacizumab in patients with metastatic colorectal cancer.
Clin Colorectal Cancer. 12:248–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Trarbach T, Moehler M, Heinemann V, Köhne
CH, Przyborek M, Schulz C, Sneller V, Gallant G and Kanzler S:
Phase II trial of mapatumumab, a fully human agonistic monoclonal
antibody that targets and activates the tumour necrosis factor
apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with
refractory colorectal cancer. Br J Cancer. 102:506–512. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rocha Lima CM, Bayraktar S, Flores AM,
MacIntyre J, Montero A, Baranda JC, Wallmark J, Portera C, Raja R,
Stern H, et al: Phase Ib study of drozitumab combined with
first-line mFOLFOX6 plus bevacizumab in patients with metastatic
colorectal cancer. Cancer Invest. 30:727–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fuchs CS, Fakih M, Schwartzberg L, Cohn
AL, Yee L, Dreisbach L, Kozloff MF, Hei YJ, Galimi F, Pan Y, et al:
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus
bevacizumab for first-line treatment of metastatic colorectal
cancer: A randomized phase 1b/2 trial. Cancer. 119:4290–4298. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takeda K, Stagg J, Yagita H, Okumura K and
Smyth MJ: Targeting death-inducing receptors in cancer therapy.
Oncogene. 26:3745–3757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Do MT, Na M, Kim HG, Khanal T, Choi JH,
Jin SW, Oh SH, Hwang IH, Chung YC, Kim HS, et al: Ilimaquinone
induces death receptor expression and sensitizes human colon cancer
cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38
MAPK-CHOP signaling pathways. Food Chem Toxicol. 71:51–59. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu GS, Burns TF, McDonald ER III, Jiang W,
Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, et al:
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor
gene. Nat Genet. 17:141–143. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ohtsuka T and Zhou T: Bisindolylmaleimide
VIII enhances DR5-mediated apoptosis through the MKK4/JNK/p38
kinase and the mitochondrial pathways. J Biol Chem.
277:29294–29303. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shenoy K, Wu Y and Pervaiz S: LY303511
enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via
hydrogen peroxide-mediated mitogen-activated protein kinase
activation and up-regulation of death receptors. Cancer Res.
69:1941–1950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bruhat A, Jousse C, Wang XZ, Ron D,
Ferrara M and Fafournoux P: Amino acid limitation induces
expression of CHOP, a CCAAT/enhancer binding protein-related gene,
at both transcriptional and post-transcriptional levels. J Biol
Chem. 272:17588–17593. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Flo TH, Smith KD, Sato S, Rodriguez DJ,
Holmes MA, Strong RK, Akira S and Aderem A: Lipocalin 2 mediates an
innate immune response to bacterial infection by sequestrating
iron. Nature. 432:917–921. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Candido S, Maestro R, Polesel J, Catania
A, Maira F, Signorelli SS, McCubrey JA and Libra M: Roles of
neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.
Oncotarget. 5:1576–1594. 2014. View Article : Google Scholar : PubMed/NCBI
|
